Petros Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $1.9M | $-14.3M | $-8.2M | $-20.0M | $-9.0M | $-20.6M |
| Depreciation & Amortization | — | $2.8M | $3.3M | $5.6M | $6.9M | $6.7M |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | $2.8M | $3.3M | $5.6M | $6.9M | — |
| Stock-Based Compensation | $304.6K | $197.2K | $417.2K | $1.2M | $1.3M | — |
| Net Cash from Operating Activities | $-6.7M | $-2.6M | $-7.6M | $-12.8M | $-11.9M | $-15.3M |
| Investing Activities | ||||||
| Capital Expenditures | — | $24.6K | — | — | — | $4.6K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-24.6K | — | — | — | $-4.6K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $8.2M | $-7.0M | $11.5M | $-1.6M | $18.6M | $30.3M |
| Net Change in Cash | — | $-9.6M | $3.9M | $-14.4M | $6.7M | $15.0M |
| Free Cash Flow | — | $-2.6M | — | — | — | $-15.3M |